The Life History of 21 Breast Cancers

作者：Serena Nik‐Zainal, Peter Van Loo, David C. Wedge, Ludmil B. Alexandrov, Christopher D. Greenman, King Wai Lau, Keiran M. Raine, David Jones, John Marshall, Manasa Ramakrishna, Adam Shlien, Susanna L. Cooke, Jonathan Hinton, Andrew H. Menzies, Lucy A. Stebbings, Catherine Leroy, Mingming Jia, Richard Rance, Laura J. Mudie, Stephen J. Gamble, Philip J. Stephens, Stuart McLaren, Patrick S. Tarpey, Elli Papaemmanuil, Helen Ruth Davies, Ignacio Pujol Varela, David J. McBride, Graham R. Bignell, Kenric Leung, Adam P. Butler, Jon W. Teague, Sancha Martin, Goran B Jönsson, Odette Mariani, Sandrine Boyault, Penelope L. Miron, Aquila Fatima, Anita Langerød, Samuel A. J. R. Aparicio, Andrew N.J. Tutt, Anieta M. Sieuwerts, Åke Borg, Gilles Thomas, Anne Vincent Salomon, Andrea L. Richardson, Anne‐Lise Børresen‐Dale, P. Andrew Futreal, Michael R. Stratton, Peter J. Campbell · 发表于：Cell · 年份：2012 · DOI：10.1016/j.cell.2012.04.023 · 被引用次数：1553 · 研究领域：Cancer Genomics and Diagnostics、Genetic factors in colorectal cancer、Single-cell and spatial transcriptomics

Cancer evolves dynamically as clonal expansions supersede one another driven by shifting selective pressures, mutational processes, and disrupted cancer genes. These processes mark the genome, such that a cancer's life history is encrypted in the somatic mutations present. We developed algorithms to decipher this narrative and applied them to 21 breast cancers. Mutational processes evolve across a cancer's lifespan, with many emerging late but contributing extensive genetic variation. Subclonal diversification is prominent, and most mutations are found in just a fraction of tumor cells. Every tumor has a dominant subclonal lineage, representing more than 50% of tumor cells. Minimal expansion of these subclones occurs until many hundreds to thousands of mutations have accumulated, implying the existence of long-lived, quiescent cell lineages capable of substantial proliferation upon acquisition of enabling genomic changes. Expansion of the dominant subclone to an appreciable mass may therefore represent the final rate-limiting step in a breast cancer's development, triggering diagnosis.